Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Silver will perform like gold on steroids

This past March, I asked a highly successful investment advisor what he thought about gold. Since he deals almost exclusively with very high net-worth individuals, his point of view was especially intriguing. He confided to me that many of his clients had been asking for g...
Peter Krauth | December 10, 2012 |

April 21st 2020, Crypto Chartbook: Uncertainty – opportunity in disguise

Uncertainty – opportunity in disguise We have just entered into a future with a higher degree of uncertainty. Times of more rapid change promise innovation, a higher degree of risk taking, in short evolution on steroids awaits. History shows that times like these spell op...
Korbinian Koller | April 22, 2020 |

Biotech's DMD Therapeutic 'Solidifies the Ground for Potential Pivotal Design'

The latest development concerning this clinical asset and other Q2/19 highlights are provided in an H.C. Wainwright & Co. report. In an Aug. 8 research note, analyst Joseph Pantginis reviewed Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Q2/19 financials and reported t...
Streetwise Reports | August 14, 2019 |

Aurinia Pharma Shares Open 100% Higher on Phase 3 Lupus Data

Shares of Aurinia Pharmaceuticals traded much higher today after it reported positive results from its Phase 3 AURORA trial of Voclosporin for treatment of lupus nephritis. The company plans to submit a New Drug Application to the FDA in H1/20. Yesterday afternoon, Vi...
Streetwise Reports | December 7, 2019 |

Better Than Buy-and-Hold Gold Investment

Have you thought about simply buying gold and forgetting about it for the next 10-15 years? We certainly did. And it seems not bad. But is „not bad” enough? Better Than Buy-and-Hold Gold Investment We were asked to comment on a specific long-term i...
Przemyslaw Radomski, CFA | May 30, 2019 |

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

The compelling aspects of this life sciences story are presented in a Dawson James report. In a Jan. 28 research note, analyst Jason Kolbert reported that Dawson James Securities increased its target price on Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX) to $15 pe...
Streetwise Reports | February 3, 2020 |

Precious 'Mettle'

"Mettle"—the ability to cope with difficulties or to face a demanding situation in a spirited and resilient way. Given the performance of my beloved Gold and Gold Miners in the past month, could there have ever been a more fitting word describing our sector than in the ...
Streetwise Reports | July 6, 2019 |

The Post-reversal Rallies and Upside Targets for GDX, GDXJ

Yesterday, we told our subscribers that probably all markets (or most thereof) are about to correct. And it seems that’s exactly what is happening. Crude oil is moving higher . The USD Index declined from 103.82 to about 102.72 (at the moment of writing these ...
Przemyslaw Radomski, CFA | March 20, 2020 |

MMT is a spectacularly Dem idea

Economists are good for one thing, and that is creating theories. The trouble is, those theories are often wrong. This is why economics is often called “the dismal science”. Such is the case with the latest economic soup-de-jour, Modern Monetary Theory, o...
Richard (Rick) Mills | April 12, 2019 |

Beware the Feint

Precious metals expert Michael Ballanger looks at the recent run-up in gold and reveals his recent trades. I am so confused tonight that I had to crowbar the booze cabinet in order to calm my scrambled soul and ease the pain in my pseudo-analytical chest. Th...
Streetwise Reports | June 26, 2019 |
1 2
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested